Search details
1.
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.
Nat Chem Biol
; 14(8): 768-777, 2018 08.
Article
in English
| MEDLINE | ID: mdl-29942081
2.
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Nat Commun
; 15(1): 3741, 2024 May 03.
Article
in English
| MEDLINE | ID: mdl-38702301
3.
Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer.
Mol Cancer Ther
; 20(4): 655-664, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33536192
4.
Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility.
Nat Commun
; 11(1): 2375, 2020 05 12.
Article
in English
| MEDLINE | ID: mdl-32398776
5.
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Nat Med
; 25(1): 111-118, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30478424
6.
A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance.
Cell Rep
; 23(3): 918-929, 2018 Apr 17.
Article
in English
| MEDLINE | ID: mdl-29669295
7.
Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
Mol Cancer Ther
; 14(11): 2411-21, 2015 Nov.
Article
in English
| MEDLINE | ID: mdl-26333382
8.
AKT-induced tamoxifen resistance is overturned by RRM2 inhibition.
Mol Cancer Res
; 12(3): 394-407, 2014 Mar.
Article
in English
| MEDLINE | ID: mdl-24362250
9.
Estrogen, tamoxifen, and Akt modulate expression of putative housekeeping genes in breast cancer cells.
J Steroid Biochem Mol Biol
; 125(3-5): 219-25, 2011 Jul.
Article
in English
| MEDLINE | ID: mdl-21420492
Results
1 -
9
de 9
1
Next >
>>